ClinicalTrials.gg
Enrolling by invitationNCT07346534Updated Oct 22, 2026

Reinforced Versus Conventional Anastomosis in Laparoscopic Low Rectal Cancer Resection: A Comparative Study

An interventional study of Reinforced Anastomotic Suturing (8-10 Interrupted Sutures) and Conventional Laparoscopic Dixon Procedure in Low Rectal Cancer, Rectal Neoplasms and Colorectal Cancer, sponsored by Shanghai 10th People's Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Shanghai 10th People's Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 years 1 month after the study started (first participant enrolled Jun 2022, registered Jul 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 463 studies in Rectal Neoplasms with a site in China — 228 open to participants now, 267 under way, 42 of them phase 3. Rectal Neoplasms · China.

Planned enrollment
68th of 373
300 · median 100
Started
2022
with 42 others
No phase
133 of 463
58 open now
Primary completion
2026-12
later than 130 of 266 live
Registered
373rd of 463
by date

Among the 463 studies in Rectal Neoplasms with a site in China, this one is the 68th largest by planned enrollment of the 373 interventional ones that give a count, is one of 43 that started in 2022, is one of 133 with no phase, reaches primary completion later than 130 of the 266 other live ones, and was the 373rd registered.

Rectal Neoplasms

2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

228 of the 463 studies in Rectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

223 more — sign in →

All 228 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 463 studies in Rectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

Study Description This prospective, controlled clinical study aims to compare the clinical outcomes of reinforced anastomosis using 8-10 interrupted sutures versus the conventional Dixon procedure in patients undergoing laparoscopic low anterior resection for low rectal cancer. Anastomotic leakage remains one of the most significant postoperative complications following low rectal cancer surgery, particularly in laparoscopic procedures due to limited tactile feedback and maneuverability in the pelvic cavity.

Reinforcement of the anastomotic site through additional interrupted suturing may provide better mechanical strength and improved healing, potentially reducing the incidence of anastomotic leakage and related morbidities. In this study, eligible patients will be assigned to receive either a conventional laparoscopic Dixon procedure or the same procedure with added reinforcement of the anastomosis using 8-10 interrupted sutures circumferentially.

Perioperative outcomes including the rate of anastomotic leakage, postoperative complications, operation time, length of hospital stay, return of bowel function, and quality of life will be assessed and compared between the two groups. The study seeks to provide evidence for optimizing surgical techniques in low rectal cancer treatment and improving patient prognosis.

03

Conditions studied

  • Low Rectal Cancer
  • Rectal Neoplasms
  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 85 years.
  2. Diagnosed with low rectal adenocarcinoma located within 7 cm from the anal verge by colonoscopy and .
  3. Scheduled for elective laparoscopic low anterior resection (Dixon procedure).
  4. Clinical stage I-III (based on preoperative imaging, e.g., MRI/CT) without distant .
  5. Adequate organ function (hematologic, hepatic, renal) to tolerate surgery.
  6. Provided written and willing to comply with study procedures and follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Presence of synchronous distant or other .
  2. History of prior pelvic radiotherapy or major pelvic surgery.
  3. Severe uncontrolled comorbidities (e.g., severe cardiovascular, respiratory, hepatic or renal insufficiency).
  4. Emergency surgery indication (e.g., bowel obstruction, perforation).
  5. Pregnancy or breastfeeding.
  6. Known allergy or to anesthesia or surgical materials used.
  7. Participation in another interventional clinical trial within the last 3 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Reinforced Anastomosis with 8-10 Interrupted Sutures

    Patients in this group will undergo laparoscopic low anterior resection (Dixon procedure) for low rectal cancer, followed by reinforcement of the anastomosis using 8-10 interrupted seromuscular sutures circumferentially around the stapled anastomotic site. The reinforcement is intended to enhance anastomotic integrity and reduce the risk of leakage.

    Procedure: Reinforced Anastomotic Suturing (8-10 Interrupted Sutures)

  • Active comparator
    Conventional Dixon Procedure

    Patients in this group will undergo standard laparoscopic low anterior resection (Dixon procedure) for low rectal cancer without additional reinforcement of the anastomosis. The anastomosis will be performed using a circular stapler alone, as per conventional practice.

    Procedure: Conventional Laparoscopic Dixon Procedure

Interventions

  • ProcedureReinforced Anastomotic Suturing (8-10 Interrupted Sutures)

    After completing the laparoscopic low anterior resection (Dixon procedure) for low rectal cancer, the surgeon performs additional reinforcement of the colorectal anastomosis. This is done by placing 8 to 10 interrupted seromuscular sutures circumferentially around the anastomotic site. The goal of this reinforcement is to enhance anastomotic stability, promote healing, and reduce the risk of anastomotic leakage.

  • ProcedureConventional Laparoscopic Dixon Procedure

    Patients undergo standard laparoscopic low anterior resection (Dixon procedure) for low rectal cancer. The colorectal anastomosis is performed using a circular stapler without any additional suturing or reinforcement. This represents the conventional surgical approach widely used in clinical practice.

06

What researchers measure

Primary outcomes

  1. Incidence of Anastomotic Leakage

    Defined as clinically significant leakage confirmed by radiological or surgical evidence, classified according to International Study Group of Rectal Cancer (ISREC) criteria.

    Time frame: Within 30 days postoperatively

Secondary outcomes

  1. Postoperative Complication Rate

    Incidence of Clavien-Dindo grade II or higher complications.

    Time frame: Up to 30 days after surgery

  2. Operation Time

    Total duration of surgery from skin incision to skin closure.

    Time frame: During the surgical procedure

  3. Length of Postoperative Hospital Stay

    Number of days from surgery to hospital discharge.

    Time frame: From date of surgery through date of discharge, up to 30 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 54 months is close to that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Jan 16, 2026
StartActual
Jun 1, 2022
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07346534
Responsible party
Zhang Feng-Min (Investigator assistant, Shanghai 10th People's Hospital) — Principal investigator
First posted
Jan 16, 2026
Start date
Jun 1, 2022
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion